Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00195234 | Study Evaluating Vaccine in Adults With HIV | PHASE1 | COMPLETED | 60 | — | — | Dec 1, 2004 | Feb 1, 2007 | Dec 5, 2007 | 10 | United States |
| Name | Type | Description |
|---|---|---|
| HIV CTL MEP 1000 micrograms, 19 months per subject | BIOLOGICAL | - |
Inclusion Criteria: * 18 years of age diagnosed with HIV and on stable HAART for a minimum of six months * CD4 T-cell count greater than and equal to 350/mm3 at screening * No reported CD4 T-cell count less than 350/mm3 at any time before screening * Viral load less than 50 copies/mL at screening a...